Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia

AIM OF THE STUDY: Resistance to imatinib is one of the most important issues in treatment of chronic myeloid leukemia (CML) patients. The objective of the study was to analyze the ex vivo drug resistance profile to bortezomib and 22 other antileukemic drugs, including three tyrosine kinase inhibitor...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Styczyński, Jan, Gil, Lidia, Czyżewski, Krzysztof, Kołodziej, Beata, Kuryło-Rafińska, Beata, Lewandowski, Krzysztof, Gniot, Michał, Lewandowska, Maria, Komarnicki, Mieczysław, Wysocki, Mariusz
格式: Artigo
語言:Inglês
出版: Termedia Publishing House 2012
主題:
Original Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3687416/
https://ncbi.nlm.nih.gov/pubmed/23788881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2012.29286
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍